Royalty Pharma (NASDAQ:RPRX) is preparing to release its quarterly earnings on Wednesday, 2026-02-11. Here’s a brief overview of what investors should keep in mind before the announcement.
Analysts expect Royalty Pharma to report an earnings per share (EPS) of $1.33.
Anticipation surrounds Royalty Pharma’s announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
Historical Earnings Performance
During the last quarter, the company reported an EPS beat by $0.10, leading to a 0.89% increase in the share price on the subsequent day.
Here’s a look at Royalty Pharma’s past performance and the resulting price change:
| Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| EPS Estimate | 1.07 | 1.05 | 0.950 | 1.05 |
| EPS Actual | 1.17 | 1.14 | 1.057 | 1.16 |
| Price Change % | 1.00 | 0.00 | 0.000 | 0.00 |
Royalty Pharma Share Price Analysis
Shares of Royalty Pharma were trading at $44.05 as of February 09. Over the last 52-week period, shares are up 36.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Views on Royalty Pharma
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Royalty Pharma.
Analysts have provided Royalty Pharma with 2 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $47.5, suggesting a potential 7.83% upside.